Later, we will discuss how known oncogenes in cancer-promoting molecular pathways are likely to be amplified in GE cancer rather than mutated in a gain-of-function fashion, which is typically the predominant mechanism of alteration for oncogenes in CRC (e.g., KRAS). Here, KRAS is linked to colorectal carcinoma.